Detalhe da pesquisa
1.
Determinants of cancer drug pricing and how to overcome the cancer premium.
Cell
; 186(8): 1528-1531, 2023 04 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37059061
2.
Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020.
Ann Intern Med
; 176(10): 1413-1418, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37844306
3.
Approval and therapeutic value of gene therapies in the US and Europe.
Gene Ther
; 30(10-11): 756-760, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37935853
4.
Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Lancet Oncol
; 23(4): 514-520, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35271804
5.
Sources of Innovation in Gene Therapies - Approaches to Achieving Affordable Prices.
N Engl J Med
; 388(4): 292-295, 2023 01 26.
Artigo
Inglês
| MEDLINE | ID: mdl-36688504
6.
Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period.
J Natl Compr Canc Netw
; : 1-9, 2021 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34560672
7.
Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Lancet Oncol
; 21(5): 664-670, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32359489
8.
Shortages of essential cancer medicines: who is responsible and what are the possible solutions?
Lancet Oncol
; 25(1): 23-26, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38181805
9.
Vertebral body insufficiency fractures: detection of vertebrae at risk on standard CT images using texture analysis and machine learning.
Eur Radiol
; 29(5): 2207-2217, 2019 May.
Artigo
Inglês
| MEDLINE | ID: mdl-30519934
10.
Reforms to accelerated approval of new medicines: long overdue.
Lancet
; 400(10349): 357-358, 2022 07 30.
Artigo
Inglês
| MEDLINE | ID: mdl-35835129
11.
New EU regulation on health technology assessment of cancer medicines.
Lancet Oncol
; 23(2): e58, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35114127
12.
Reforming the World Health Organization's Essential Medicines List: Essential but Unaffordable.
JAMA
; 328(18): 1807-1808, 2022 11 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36279114
13.
Lifecycle Regulation of Artificial Intelligence- and Machine Learning-Based Software Devices in Medicine.
JAMA
; 322(23): 2285-2286, 2019 12 17.
Artigo
Inglês
| MEDLINE | ID: mdl-31755907
14.
FDA-cleared artificial intelligence and machine learning-based medical devices and their 510(k) predicate networks.
Lancet Digit Health
; 5(9): e618-e626, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37625896
15.
Defining 'therapeutic value' of medicines: a scoping review.
BMJ Open
; 13(12): e078134, 2023 12 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38110384
16.
The cancer premium - explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study.
EClinicalMedicine
; 61: 102087, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37521033
17.
Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study.
BMJ
; 382: e074166, 2023 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37407074
18.
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
JAMA Health Forum
; 3(8): e222685, 2022 08 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36200635
19.
Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland.
JAMA Netw Open
; 5(12): e2244670, 2022 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36459139
20.
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
JCO Oncol Pract
; 18(9): e1522-e1532, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35731996